Cat. No.: HY-189570

TMLB-G9

TMLB-G9 is an orally active B3GAT3 inhibitor (human K_d = 0.72 μM). TMLB-G9 blocks glycosaminoglycan biosynthesis and inhibits chondroitin sulfate biosynthesis in hepatocellular carcinoma cells. TMLB-G9 induces apoptosis by upregulating cleaved PARP and cleaved caspase-3. TMLB-G9 induces G0/G1 cell cycle arrest by upregulating Rb and downregulating CDK1, CDK2, Cyclin A2, Cyclin E1, and phosphorylated Rb. TMLB-G9 inhibits migration and invasion by reversing epithelial-mesenchymal transition, manifested as upregulation of E-cadherin and downregulation of N-cadherin, vimentin, MMP-2, MMP-9, and ZEB1. TMLB-G9 inhibits colony formation. TMLB-G9 exhibits broad-spectrum antitumor activity against multiple cancer cell lines. TMLB-G9 can be used for research on hepatocellular carcinoma.

For research use only. We do not sell to patients.

CAS No.: 3127781-85-2
Formula: C₃₃H₂₆N₄O₇
Molecular Weight:590.58

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

TMLB-G9 Chemical Structure

CAS No.: 3127781-85-2

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- Parmacokinetics
- In Vivo
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target

^[1]

CDK1

CDK2

MMP-9

Caspase 3

MMP-2

All PARP Isoforms :

All Caspase Isoforms :

All CDK Isoforms :

All MMP Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
Huh-7	IC50	0.36 μM	Antiproliferative activity against Huh7 cells assessed as viability inhibition by cell viability assay. Antiproliferative activity against Huh7 cells assessed as viability inhibition by cell viability assay.	acs.jmedchem.6c02080
Hep3B	IC50	0.31 μM	Antiproliferative activity against Hep3B cells assessed as viability inhibition by cell viability assay. Antiproliferative activity against Hep3B cells assessed as viability inhibition by cell viability assay.	acs.jmedchem.6c02080
PLC-PRF-5	IC50	1.14 μM	Antiproliferative activity against PLC/PRF/5 cells assessed as viability inhibition by cell viability assay. Antiproliferative activity against PLC/PRF/5 cells assessed as viability inhibition by cell viability assay.	acs.jmedchem.6c02080
SNU-387	IC50	3.40 μM	Antiproliferative activity against SNU387 cells assessed as viability inhibition by cell viability assay. Antiproliferative activity against SNU387 cells assessed as viability inhibition by cell viability assay.	acs.jmedchem.6c02080
HCCLM3	IC50	0.35 μM	Antiproliferative activity against HCCLM3 cells assessed as viability inhibition by cell viability assay. Antiproliferative activity against HCCLM3 cells assessed as viability inhibition by cell viability assay.	acs.jmedchem.6c02080
NCI-H460	IC50	1.21 μM	Antiproliferative activity against NCI-H460 cells assessed as viability inhibition by cell viability assay. Antiproliferative activity against NCI-H460 cells assessed as viability inhibition by cell viability assay.	acs.jmedchem.6c02080
PC-3	IC50	0.13 μM	Antiproliferative activity against PC3 cells assessed as viability inhibition by cell viability assay. Antiproliferative activity against PC3 cells assessed as viability inhibition by cell viability assay.	acs.jmedchem.6c02080
AGS	IC50	1.27 μM	Antiproliferative activity against AGS cells assessed as viability inhibition by cell viability assay. Antiproliferative activity against AGS cells assessed as viability inhibition by cell viability assay.	acs.jmedchem.6c02080
HT-29	IC50	1.49 μM	Antiproliferative activity against HT29 cells assessed as viability inhibition by cell viability assay. Antiproliferative activity against HT29 cells assessed as viability inhibition by cell viability assay.	acs.jmedchem.6c02080
SW-620	IC50	0.84 μM	Antiproliferative activity against SW620 cells assessed as viability inhibition by cell viability assay. Antiproliferative activity against SW620 cells assessed as viability inhibition by cell viability assay.	acs.jmedchem.6c02080
MDA-MB-231	IC50	1.29 μM	Antiproliferative activity against MDA-MB-231 cells assessed as viability inhibition by cell viability assay. Antiproliferative activity against MDA-MB-231 cells assessed as viability inhibition by cell viability assay.	acs.jmedchem.6c02080
U-251	IC50	0.89 μM	Antiproliferative activity against U251-MG cells assessed as viability inhibition by cell viability assay. Antiproliferative activity against U251-MG cells assessed as viability inhibition by cell viability assay.	acs.jmedchem.6c02080
H4	IC50	0.85 μM	Antiproliferative activity against H4 cells assessed as viability inhibition by cell viability assay. Antiproliferative activity against H4 cells assessed as viability inhibition by cell viability assay.	acs.jmedchem.6c02080
MEG-01	IC50	3.76 μM	Antiproliferative activity against MEG01 cells assessed as viability inhibition by cell viability assay. Antiproliferative activity against MEG01 cells assessed as viability inhibition by cell viability assay.	acs.jmedchem.6c02080
Jurkat	IC50	0.46 μM	Antiproliferative activity against Jurkat cells assessed as viability inhibition by cell viability assay. Antiproliferative activity against Jurkat cells assessed as viability inhibition by cell viability assay.	acs.jmedchem.6c02080

In Vitro

TMLB-G9 inhibits the proliferation of HCC and pan-cancer cells, with IC₅₀ values as low as 0.13 μM and 0.31 μM in PC3 and Hep3B, respectively^[1].
TMLB-G9 (0.01-1 μM; 16 days) inhibits colony formation in Huh7 and Hep3B cells^[1].
TMLB-G9 (0.5-1 μM; 6-48 h) inhibits the migration and invasion of Huh7 and Hep3B cells and reverses EMT^[1].
TMLB-G9 (0.5-1 μM) induces G0/G1 cell cycle arrest in Huh7 and Hep3B cells^[1].
TMLB-G9 (0.5-1 μM) induces apoptosis in Huh7 and Hep3B cells^[1].
TMLB-G9 binds to B3GAT3 in Huh7 and Hep3B cells, with T_agg values of 52.69 °C and 57.15 °C, respectively^[1].
TMLB-G9 (48 h) inhibits chondroitin sulfate biosynthesis in Huh7 and Hep3B cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Migration Assay ^[1]

Cell Line:

Huh7 and Hep3B cells
Concentration:

1 μM (scratch assay); 0.5 and 1 μM (Transwell and EMT Western blot)
Incubation Time:

12 h (scratch assay, Huh7); 6 h (scratch assay, Hep3B); 48 h (Transwell and EMT Western blot)
Result:

Suppressed wound healing in Huh7 cells from approximately 16% to 9% at 1 μM for 12 h and in Hep3B cells from 13.68% to 3.43% at 1 μM for 6 h.
Significantly suppressed migration and invasion.
Upregulated E-cadherin and downregulated N-cadherin, vimentin, MMP-2, MMP-9, and ZEB1.

Parmacokinetics

Species	Dose	Route	F	AUC_0-t	AUC_0-∞	T_1/2	T_max	C_max	MRT_0-t	MRT_0-∞
Rat^[1]	2 mg/kg	i.v.	/	1094.81 ng·h/mL	1097.32 ng·h/mL	1.03 h	0.08 h	2493.82 ng/mL	0.52 h	0.54 h
Rat^[1]	5 mg/kg	i.p.	11.37 %	311.07 ng·h/mL	318.71 ng·h/mL	4.41 h	5.33 h	25.37 ng/mL	7.72 h	7.80 h
Rat^[1]	10 mg/kg	p.o.	< 1 %	/	/	/	/	/	/	/

In Vivo

TMLB-G9 (5-20 mg/kg; p.o. (oral gavage); daily; for 16 consecutive days) produces dose-dependent tumor growth inhibition in the Huh7 HCC xenograft mouse model^[1].
TMLB-G9 (20 mg/kg; p.o. (oral gavage); daily; for 16 consecutive days) produces tumor growth inhibition in the HCCLM3 HCC xenograft mouse model^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

BALB/c nude^[1]
Dosage:

5 mg/kg, 10 mg/kg, and 20 mg/kg
Administration:

p.o. (oral gavage); daily; 16 consecutive days
Result:

Daily oral gavage of compound TMLB-G9 exhibited a dose-dependent tumor growth inhibition, with inhibition rates of 63.72%, 73.95%, and 83.72% at doses of 5, 10 and 20 mg/kg, respectively, which was comparable to that of lenvatinib and superior to that of compound TMLB-C16.

Animal Model:

BALB/c nude^[1]
Dosage:

20 mg/kg
Administration:

p.o. (oral gavage); daily; 16 consecutive days
Result:

The antitumor effect of compound TMLB-G9 was further confirmed in the HCCLM3-derived xenograft model, showing approximately 54.24% tumor growth inhibition at 20 mg/kg.

Related Protocols :

Chemical Information

CAS No. 3127781-85-2
Molecular Weight 590.58
Formula C₃₃H₂₆N₄O₇
SMILES

O=C(OC)C1=CC=C(NC=C2C(C(NCCNC(C3=CC(C4=CC(C=CC=C5)=C5O4)=NC(C3=C6)=CC=C6OC)=O)=O)=O)C2=C1
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Yin H, et al. Structure-Guided Design, Synthesis, and Evaluation of Novel 6-Methoxyquinoline-4-carboxamide Derivatives as First-in-Class Nano-Molar B3GAT3 Inhibitors for the Treatment of Hepatocellular Carcinoma. Journal of Medicinal Chemistry. 2026 Sep 24;69(18):21440-82.

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

TMLB-G9

All PARP Isoforms

All Caspase Isoforms

All CDK Isoforms

All MMP Isoforms